Testing lower doses of JAK inhibitors for rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have rheumatoid arthritis that meets standard medical criteria.
- You must have been taking a full dose of a JAK inhibitor for at least 6 months.
- Your disease must be well controlled (low disease activity) for at least 6 months.
- You must not have had a flare-up in the last 6 months.
- You must not be taking certain other arthritis medications like biologics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if reducing the dose of a JAK inhibitor can keep your inflammatory arthritis under control. If you have rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis and are in a stable remission, you may be able to take a lower dose.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
This study compares two newer oral medications—tofacitinib and upadacitinib—to see which works better and is safer when added to methotrexate for rheumatoid arthritis. Both medicines help calm the immune system's attack on joints.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This trial compares a newer type of medication called JAK inhibitors to standard treatments for rheumatoid arthritis (RA). It aims to see which works better for managing symptoms.
Hear when a new Rheumatoid Arthritis (RA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.